State Key Laboratory of Natural Medicines, China Pharmaceutical University, Nanjing 210009, PR China.
Bioorg Med Chem Lett. 2013 Apr 1;23(7):1985-8. doi: 10.1016/j.bmcl.2013.02.035. Epub 2013 Feb 15.
A series of novel nitric oxide releasing derivatives of 6-amino-3-n-butylphthalide were designed, synthesized and evaluated as potential antiplatelet agents. Compound 10b significantly inhibited the adenosine diphosphate (ADP)-induced platelet aggregation in vitro, superior to 6-amino-3-n-butylphthalide, 3-n-butylphthalide (NBP) and ticlopidine. Meanwhile 10b released moderate levels of NO, which could be beneficial for improving cardiovascular and cerebral circulation. Furthermore, 10b had an enhanced aqueous solubility relative to NBP. These findings may provide new insights into the development of novel antiplatelet agents for the treatment of thrombosis-related ischemic stroke.
设计、合成并评价了一系列新型的 6-氨基-3-正丁基邻苯二甲酰亚胺一氧化氮供体型衍生物,作为潜在的抗血小板药物。化合物 10b 显著抑制了体外的二磷酸腺苷(ADP)诱导的血小板聚集,优于 6-氨基-3-正丁基邻苯二甲酰亚胺、3-正丁基邻苯二甲酰亚胺(NBP)和噻氯匹定。同时,10b 释放出中等水平的一氧化氮,这可能有利于改善心血管和脑循环。此外,10b 的水溶性相对于 NBP 有所提高。这些发现可能为开发新型抗血小板药物治疗血栓相关缺血性脑卒中提供新的思路。